Myelodysplastic Syndrome (MDS) Treatment Market Size

Myelodysplastic Syndrome (MDS) Treatment Market Analysis

The myelodysplastic syndrome (MDS) treatment market is projected to register a CAGR of 6.5% during the forecast period, 2022-2027.

The COVID-19 (SARS-CoV-2) pandemic has had a variety of effects on cancer patients, including diagnostic and treatment delays, blood product scarcity, and, most importantly, increased morbidity and mortality from viral infection. For instance, as per the article titled "Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the United States Epicenter of the Pandemic", published in November 2020, records were reviewed of all patients seen in the MDS clinic of a large New York City tertiary academic medical center between March 12 and May 07, 2020. Among 85 patients seen in the clinic, 23 were found to have COVID-19. Nonetheless, such factors ultimately affected cancer care, causing the therapeutic pathway for MDS patients to be disrupted. This disruption to standard clinical care was exacerbated by the fear that COVID-19 would increase morbidity and mortality in immunocompromised MDS patients. There were fewer data available to guide treatment or protective recommendations in the early days of the pandemic, and advice was limited to expert opinion. Care interruptions had manifested as limited access to laboratory appointments for blood work assessment patients whose diseases required close observation and monitoring. Thus, the blood shortage had a significant impact on patients who required transfusional support, particularly those who lived in regions with few transfusion facilities. Patients undergoing chemotherapy also had to contend with shortened clinic or infusion center hours and inaccessible providers.

Furthermore, ongoing concern among chemotherapy patients that the resulting immunosuppression could make them more susceptible to COVID-19 infection and severe disease has shifted the balance between the risks and benefits of chemotherapy in many cases. As a result of the COVID-19 pandemic, the market studied has been impacted to a greater extent. However, with ongoing vaccinations and decreasing COVID-19 cases, the market studied is expected to regain its full potential during the forecast period.

The global market for myelodysplastic syndrome (MDS) treatment is expected to grow significantly over the coming years, owing to rising pipeline products and product approvals, as well as increased R&D investments in the development of novel drugs for MDS. For instance, Inqovi (decitabine and cedazuridine) tablets were approved by the United States Food and Drug Administration in July 2020 for the treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This is a significant advancement in treatment options for patients with MDS, a type of blood cancer which previously required intravenous therapy at a healthcare facility.

Thus, the aforementioned factors are anticipated to contribute to the growth of the myelodysplastic syndrome (MDS) treatment market. However, side effects associated with the medications are likely to impede the market's growth.